Secreted phosphoprotein 1 (SPP1) (SPP1)

Secreted phosphoprotein 1 (SPP1), widely known as Osteopontin (OPN), is a multifunctional matricellular glycoprotein that plays a critical role in immune modulation, bone remodeling, and tissue repair [1, 2, 4]. It is secreted by various cell types, including osteoblasts, macrophages, and activated T cells, and functions as both a structural component of the extracellular matrix and a soluble cytokine [2, 5, 10]. SPP1 exerts its biological effects by binding to several cell surface receptors, most notably integrins (such as αvβ3 and α4β1) and CD44, thereby activating signaling cascades like PI3K/Akt and NF-κB that promote cell survival, migration, and inflammation [2, 4, 8]. In disease states, SPP1 is frequently overexpressed and serves as a key driver of cancer progression, fibrosis, and autoimmune disorders [1, 3, 12, 13]. In the tumor microenvironment, SPP1 produced by tumor-associated macrophages (TAMs) promotes an immunosuppressive niche, facilitates epithelial-mesenchymal transition (EMT), and enhances metastasis, often correlating with poor patient prognosis [6, 25, 31]. Therapeutic strategies targeting SPP1 include neutralizing monoclonal antibodies, aptamers, and small molecule modulators designed to disrupt its interaction with receptors or reduce its expression [6, 19, 30, 32]. While several candidates like ASK8007 have reached clinical trials, challenges such as high physiological turnover and target redundancy remain significant hurdles in developing effective SPP1-targeted therapies [19, 30].

Other names

OsteopontinOPNBone sialoprotein 1BSP-1Early T-lymphocyte activation 1ETA-1NephropontinUrinary stone proteinUropontinBNSP

The primary mechanism of action for drugs targeting Secreted phosphoprotein 1 involves the neutralization of the secreted protein to prevent its interaction with cell surface receptors, such as integrins (αvβ3, αvβ5, αvβ1, α4β1, α9β1) and CD44 [2, 4, 30, 32]. This blockade inhibits downstream oncogenic and pro-inflammatory signaling pathways, including PI3K/Akt, MAPK, and NF-κB [2, 4, 8]. Additionally, novel therapeutic approaches aim to downregulate SPP1 expression directly within specific cell populations, such as tumor-associated macrophages (TAMs), to reverse immunosuppression and enhance anti-tumor immune responses [6, 25, 26].